Cantor Fitzgerald Comments on Verona Pharma FY2025 Earnings

Verona Pharma plc (NASDAQ:VRNA) – Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Verona Pharma in a research note issued to investors on Monday, April 21st. Cantor Fitzgerald analyst O. Brayer forecasts that the company will earn $0.11 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $80.00 target price on the stock. The consensus estimate for Verona Pharma’s current full-year earnings is ($1.95) per share.

A number of other research firms also recently commented on VRNA. Roth Mkm initiated coverage on shares of Verona Pharma in a report on Friday, January 10th. They issued a “buy” rating and a $68.00 price objective for the company. Truist Financial reiterated a “buy” rating and set a $57.00 price objective (up previously from $44.00) on shares of Verona Pharma in a research note on Wednesday, January 8th. Roth Capital set a $83.00 target price on Verona Pharma in a report on Friday, February 28th. Canaccord Genuity Group raised their price target on Verona Pharma from $44.00 to $72.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Finally, Wells Fargo & Company upped their price objective on Verona Pharma from $74.00 to $93.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $75.43.

Verona Pharma Trading Up 2.1 %

NASDAQ:VRNA opened at $63.31 on Wednesday. Verona Pharma has a 52 week low of $11.39 and a 52 week high of $70.40. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93. The company has a market cap of $5.12 billion, a PE ratio of -32.97 and a beta of 0.16. The business’s 50 day moving average is $62.37 and its two-hundred day moving average is $50.09.

Insider Activity at Verona Pharma

In related news, insider Kathleen A. Rickard sold 79,264 shares of Verona Pharma stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $8.35, for a total value of $661,854.40. Following the transaction, the insider now directly owns 2,608,976 shares in the company, valued at $21,784,949.60. The trade was a 2.95 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 4.80% of the company’s stock.

Institutional Trading of Verona Pharma

Hedge funds have recently bought and sold shares of the company. Stifel Financial Corp purchased a new position in Verona Pharma during the 3rd quarter worth approximately $474,000. Sanctuary Advisors LLC acquired a new stake in Verona Pharma during the 3rd quarter worth about $219,000. Franklin Resources Inc. purchased a new position in Verona Pharma during the 3rd quarter valued at about $16,103,000. GAMMA Investing LLC boosted its stake in shares of Verona Pharma by 20.7% during the 4th quarter. GAMMA Investing LLC now owns 1,612 shares of the company’s stock valued at $75,000 after buying an additional 276 shares during the period. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in shares of Verona Pharma by 24.3% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 193,707 shares of the company’s stock worth $8,996,000 after acquiring an additional 37,872 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.